NCT02095444

Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection

Phase1 Study of Recombinant Stem Cells That Repair Lung Injury in H7N9 Infected Patients

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: S-Evans Biosciences Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether human menstrual blood-derived stem cells are effective in the treatment of infection of H7N9 virus caused acute lung injury.

Detailed description

1. recruiting volunteers of H7N9 infection: age \> 18; patients signed with the informed consent; APACHE II \> 20 score 2. patients infused with menstrual blood progenitor cells infusion dose: 1\~10×10\*7 cells/kg infusion frequency: 2 times a week, 2 weeks for infusion 3. test items and standard spirits lifted; pulmonary function improved; lung image injury improved

Conditions

• Acute Lung Injury
• Acute Respiratory Distress Syndrome (ARDS)
• Multiple Organ Failure

Interventions

Type	Name	Description
DRUG	Menstrual blood stem cells	10\*7 cells/kg, intravenous injection for 4 times during two weeks

Timeline

• Start date: 2014-03-01
• Primary completion: 2016-06-01
• Completion: 2016-12-01
• First posted: 2014-03-24
• Last updated: 2014-03-24

Locations

1 site across 1 country: China